Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target
In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor for type 2 diabetes/T2D, and BMF-650, an oral GLP-1 receptor agonist...








